M C A Müller1, M Straat1, J C M Meijers2,3, J H Klinkspoor4, E de Jonge5, M S Arbous5, M J Schultz1, M B Vroom1, N P Juffermans1. 1. Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 2. Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 3. Department of Plasma Proteins, Sanquin Research, Amsterdam, the Netherlands. 4. Department of Clinical Chemistry, Academic Medical Center, Amsterdam, the Netherlands. 5. Department of Intensive Care Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Abstract
BACKGROUND: Coagulopathy has a high prevalence in critically ill patients. An increased International Normalized Ratio (INR) is a common trigger to transfuse fresh frozen plasma (FFP), even in the absence of bleeding. Therefore, FFP is frequently administered to these patients. However, the efficacy of FFP in correcting hemostatic disorders in non-bleeding recipients has been questioned. OBJECTIVES: To assess whether INR prolongation parallels changes in the results of other tests investigating hemostasis, and to evaluate the coagulant effects of a fixed dose of FFP in non-bleeding critically ill patients with a coagulopathy. METHODS:Markers of coagulation, individual factor levels and levels of natural anticoagulants were measured. Also, thrombin generation and thromboelastometry (ROTEM) assays were performed before and after FFP transfusion (12 mL kg(-1) ) to 38 non-bleeding critically ill patients with an increased INR (1.5-3.0). RESULTS: At baseline, levels of factor II, FV, FVII, protein C, protein S and antithrombin were reduced, and thrombin generation was impaired. ROTEM variables were within reference ranges, except for a prolonged INTEM clot formation time. FFP transfusion increased the levels of coagulation factors (FII, 34% [interquartile range (IQR) 26-46] before vs. 44% [IQR 38-52] after; FV, 48% [IQR 28-76] before vs. 58% [IQR 44-90] after; and FVII, 25% [IQR 16-38] before vs. 37% [IQR 28-55] after), and the levels of anticoagulant proteins. Thrombin generation was unaffected by FFP transfusion (endogenous thrombin potential, 72% [IQR 51-88] before vs. 71% [IQR 42-89] after), whereas ROTEM EXTEM clotting time and maximum clot firmness slightly improved in response to FFP. CONCLUSION: In non-bleeding critically ill patients with a coagulopathy, FFP transfusion failed to induce a more procoagulant state.
RCT Entities:
BACKGROUND:Coagulopathy has a high prevalence in critically illpatients. An increased International Normalized Ratio (INR) is a common trigger to transfuse fresh frozen plasma (FFP), even in the absence of bleeding. Therefore, FFP is frequently administered to these patients. However, the efficacy of FFP in correcting hemostatic disorders in non-bleeding recipients has been questioned. OBJECTIVES: To assess whether INR prolongation parallels changes in the results of other tests investigating hemostasis, and to evaluate the coagulant effects of a fixed dose of FFP in non-bleeding critically illpatients with a coagulopathy. METHODS: Markers of coagulation, individual factor levels and levels of natural anticoagulants were measured. Also, thrombin generation and thromboelastometry (ROTEM) assays were performed before and after FFP transfusion (12 mL kg(-1) ) to 38 non-bleeding critically illpatients with an increased INR (1.5-3.0). RESULTS: At baseline, levels of factor II, FV, FVII, protein C, protein S and antithrombin were reduced, and thrombin generation was impaired. ROTEM variables were within reference ranges, except for a prolonged INTEM clot formation time. FFP transfusion increased the levels of coagulation factors (FII, 34% [interquartile range (IQR) 26-46] before vs. 44% [IQR 38-52] after; FV, 48% [IQR 28-76] before vs. 58% [IQR 44-90] after; and FVII, 25% [IQR 16-38] before vs. 37% [IQR 28-55] after), and the levels of anticoagulant proteins. Thrombin generation was unaffected by FFP transfusion (endogenous thrombin potential, 72% [IQR 51-88] before vs. 71% [IQR 42-89] after), whereas ROTEM EXTEM clotting time and maximum clot firmness slightly improved in response to FFP. CONCLUSION: In non-bleeding critically illpatients with a coagulopathy, FFP transfusion failed to induce a more procoagulant state.
Authors: Matthew A Warner; David A Woodrum; Andrew C Hanson; Darrell R Schroeder; Gregory A Wilson; Daryl J Kor Journal: Mayo Clin Proc Date: 2016-08 Impact factor: 7.616
Authors: Matthew A Warner; Ryan D Frank; Timothy J Weister; Mark M Smith; James R Stubbs; Daryl J Kor Journal: Transfusion Date: 2018-11-01 Impact factor: 3.157
Authors: Clare A Balendran; Ann Lövgren; Kenny M Hansson; Karin Nelander; Marita Olsson; Karin J Johansson; Karim Brohi; Dietmar Fries; Anders Berggren Journal: Scand J Trauma Resusc Emerg Med Date: 2017-03-14 Impact factor: 2.953
Authors: Abdel Galil M Abdel Gader; Abeer K Al-Ghumlas; Abdul Kareem M Al Momen; Sitel Banat A Awadalla; Motasim Badri Journal: J Taibah Univ Med Sci Date: 2017-06-09
Authors: Alexander P Vlaar; Simon Oczkowski; Sanne de Bruin; Marije Wijnberge; Massimo Antonelli; Cecile Aubron; Philippe Aries; Jacques Duranteau; Nicole P Juffermans; Jens Meier; Gavin J Murphy; Riccardo Abbasciano; Marcella Muller; Akshay Shah; Anders Perner; Sofie Rygaard; Timothy S Walsh; Gordon Guyatt; J C Dionne; Maurizio Cecconi Journal: Intensive Care Med Date: 2020-01-07 Impact factor: 17.440